Levi & Korsinsky notifies investors that it has commenced an investigation into Zimmer Biomet Holdings, Inc. (NYSE: ZBH) concerning potential violations of the federal securities laws.
Zimmer Biomet issued a press release on November 5, 2025, announcing its financial results for the third quarter of 2025 and held an earnings call to discuss the same. Among other items, Zimmer Biomet reported net sales of $2 billion, missing consensus estimates of $2.01 billion. Zimmer Biomet also lowered the top end of its outlook for full-year organic revenue growth, projecting gains of 3.5% to 4%, compared to a previous range of 3.5% to 4.5%. Zimmer Biomet reported weakness in international markets and non-core businesses, while its Chief Executive Officer said that distributor challenged and a cancelation of orders in the Middle East and Eastern Europe also weighed on the Company's results. Analysts also noted lower-than-expected growth in U.S. knee and hip replacement sales, expressing concerns about Zimmer Biomet's operational controls. Following this news, Zimmer Biomet's stock price fell over 15% on November 5, 2025.
If you suffered a loss on your Zimmer Biomet Holdings, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





